Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

AAV
ADVANTAGE OIL & GAS
stock NYSE

No price data
0.00USD0.000%(0.00)0
Pre-market
0.00USD0.000%(0.00)0
After-hours
0.00USD0.000%(0.00)0
OverviewTrends
AAV Reddit Mentions
Subreddits
Limit Labels     

We have sentiment values and mention counts going back to 2017. The complete data set is available via the API.
Take me to the API
AAV Specific Mentions
As of Sep 25, 2026 1:50:58 PM EDT (1 min. ago)
Includes all comments and posts. Mentions per user per ticker capped at one per hour.
7 days ago • u/biocatalystwatch • r/Biotechplays • upcoming_catalysts_sep_26oct_14_mirm_and_bfri • News • B
Here are the dated catalysts I'm tracking over the next ~4 weeks. Each one links to the document the date came from:
- Sep 26 — $MIRM: PDUFA for zilurgisertib (oral ALK2 inhibitor) in fibrodysplasia ossificans progressiva, Priority Review. [Source: company PR](https://ir.mirumpharma.com/news/news-details/2026/Mirum-Pharmaceuticals-Reports-First-Quarter-2026-Financial-Results-and-Provides-Business-Update/default.aspx)
- Sep 28 — $BFRI: PDUFA for Ameluz in superficial basal cell carcinoma. [Source: company PR](https://investors.biofrontera-us.com/full-news/?qm-storyId=6130523632637960)
- Oct 4 — $IRD: Phase 1/2 data for OPGx-BEST1 (AAV gene therapy, BEST1-related retinal disease). [Source: company PR](https://ir.opusgtx.com/press-releases/detail/538/opus-genetics-provides-best1-program-update-with-detailed-timeline-for-opgx-best1-results)
- Oct 11 — $CRVO: Phase 2 data for neflamapimod in nonfluent variant primary progressive aphasia. [Source: Q2 results PR](https://ir.cervomed.com/news-releases/news-release-details/cervomed-reports-second-quarter-2026-financial-results-and)
- Oct 14 — $BRNS: Phase 1 data for VTP-1000 in celiac disease. [Source: 8-K exhibit](https://www.sec.gov/Archives/edgar/data/1828185/000162828026053940/brns-20260630xexx991.htm)
I left out anything guided only as "in 2026" or "2H". Those aren't dates.
Why I'm posting this: I'm the developer of BioCatalyst Watch, which is where this list comes from. Most catalyst calendars I used didn't show where a date came from, so I couldn't tell a confirmed PDUFA from a guess. On the site, every event links to the FDA document, press release, or SEC filing behind it. It also shows each company's cash position next to its catalysts, so you can see whether a raise might come before the readout.
It covers 409 U.S.-listed biotechs and is free during beta (no card). The next 30 days are viewable without signing up: https://biocatalystwatch.com/?utm_source=reddit&utm_campaign=biotechplays
I'd really like to know what's missing, what's wrong, and what would make this worth bookmarking. If a date above looks off to you, tell me. That's exactly the feedback I need.
Not investment advice. I hold no position in any ticker above.
sentiment 0.42
7 days ago • u/biocatalystwatch • r/Biotechplays • upcoming_catalysts_sep_26oct_14_mirm_and_bfri • News • B
Here are the dated catalysts I'm tracking over the next ~4 weeks. Each one links to the document the date came from:
- Sep 26 — $MIRM: PDUFA for zilurgisertib (oral ALK2 inhibitor) in fibrodysplasia ossificans progressiva, Priority Review. [Source: company PR](https://ir.mirumpharma.com/news/news-details/2026/Mirum-Pharmaceuticals-Reports-First-Quarter-2026-Financial-Results-and-Provides-Business-Update/default.aspx)
- Sep 28 — $BFRI: PDUFA for Ameluz in superficial basal cell carcinoma. [Source: company PR](https://investors.biofrontera-us.com/full-news/?qm-storyId=6130523632637960)
- Oct 4 — $IRD: Phase 1/2 data for OPGx-BEST1 (AAV gene therapy, BEST1-related retinal disease). [Source: company PR](https://ir.opusgtx.com/press-releases/detail/538/opus-genetics-provides-best1-program-update-with-detailed-timeline-for-opgx-best1-results)
- Oct 11 — $CRVO: Phase 2 data for neflamapimod in nonfluent variant primary progressive aphasia. [Source: Q2 results PR](https://ir.cervomed.com/news-releases/news-release-details/cervomed-reports-second-quarter-2026-financial-results-and)
- Oct 14 — $BRNS: Phase 1 data for VTP-1000 in celiac disease. [Source: 8-K exhibit](https://www.sec.gov/Archives/edgar/data/1828185/000162828026053940/brns-20260630xexx991.htm)
I left out anything guided only as "in 2026" or "2H". Those aren't dates.
Why I'm posting this: I'm the developer of BioCatalyst Watch, which is where this list comes from. Most catalyst calendars I used didn't show where a date came from, so I couldn't tell a confirmed PDUFA from a guess. On the site, every event links to the FDA document, press release, or SEC filing behind it. It also shows each company's cash position next to its catalysts, so you can see whether a raise might come before the readout.
It covers 409 U.S.-listed biotechs and is free during beta (no card). The next 30 days are viewable without signing up: https://biocatalystwatch.com/?utm_source=reddit&utm_campaign=biotechplays
I'd really like to know what's missing, what's wrong, and what would make this worth bookmarking. If a date above looks off to you, tell me. That's exactly the feedback I need.
Not investment advice. I hold no position in any ticker above.
sentiment 0.42


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC